Carvykti Market Report 2026

Carvykti Market Overview

• The Carvykti market growth in the historic period has been driven by limitations of conventional myeloma therapies, early success of autologous cell therapies • Market expansion is supported by increasing multiple myeloma prevalence, broader regulatory approvals • Growth Driver: Impact Of Growing Cancer Prevalence On The Carvykti Market Growth • Market Trend: Shift Toward Earlier-Line, Durable, One-Time Cellular Immunotherapies For Myeloma Patients • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Carvykti Market?

Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy used to treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. It works by genetically modifying a patient’s T cells to target and destroy cancerous plasma cells expressing the BCMA (B-cell maturation antigen) protein. The main type of carvykti is cell therapy (autologous t-cell therapy). Cell therapy, specifically autologous T-cell therapy, involves using a patient's T-cells to fight cancer. In this process, T-cells are collected from the patient's blood and modified in a laboratory to better recognize and attack cancer cells, such as those found in multiple myeloma. It is used for various indications such as multiple myeloma, and relapsed or refractory multiple myeloma for patients including adults (primarily targeting adult patients). Distributed through various channels such as hospital pharmacies, stem cell banks, and outpatient clinics.

What Is The Carvykti Market Growth Forecast?

The growth in the forecast period can be attributed to increasing multiple myeloma prevalence, broader regulatory approvals, scaling of cell therapy manufacturing, growing physician familiarity with car t protocols, expansion of specialized oncology centers. Major trends in the forecast period include expansion of car t cell therapies in hematologic cancers, rising adoption of personalized cancer treatments, growing focus on bcma targeted therapies, increasing investment in cell therapy manufacturing, centralization of advanced oncology treatment centers.

Global Carvykti Market Segmentation

1) By Type: Cell Therapy (Autologous T-Cell Therapy) 2) By Indication: Multiple Myeloma, Relapsed Or Refractory Multiple Myeloma 3) By Patient Demographics: Adults (Primarily Targeting Adult Patients) 4) By Distribution Channel: Hospital Pharmacies, Oncology Treatment Centers, Specialty Pharmacies

What Is The Driver Of The Carvykti Market?

The growing cancer prevalence will drive the growth of the carvykti market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can result in death if not treated. The growing prevalence of cancer is driven by an aging population, lifestyle factors, environmental exposures, and improved detection methods. Carvykti, a CAR T-cell therapy, is useful in addressing growing cancer prevalence by offering a targeted treatment option for relapsed or refractory multiple myeloma, improving outcomes for patients with limited alternatives. For instance, in May 2024, according to the National Cancer Institute, a US-based National Institute of Health, as of January 2022, the United States had an estimated 18.1 million cancer survivors, a number projected to rise to 22.5 million by 2032. Therefore, growing cancer prevalence boost the growth of the carvykti industry.

Key Players In The Global Carvykti Market

Major companies operating in the carvykti market are Johnson & Johnson Services Inc., Legend Biotech, Novartis AG

Global Carvykti Market Trends and Insights

The key trend in the Carvykti market is the growing focus on developing innovative products such as autologous CAR-T therapy to achieve durable, one-time remissions and enable earlier-line use in hematologic malignancies. An autologous CAR-T therapy is a personalized cell therapy produced from a patient’s own T cells that are engineered to express a chimeric antigen receptor targeting a disease-specific antigen. For instance, in April 2024, Johnson & Johnson (Janssen), a United States-based multinational pharmaceutical and biotechnology company, obtained expanded United States Food and Drug Administration approval for CARVYKTI (ciltacabtagene autoleucel) to treat adult patients with relapsed or refractory multiple myeloma after at least one prior line of therapy. The approval broadens CARVYKTI’s eligible patient population by enabling earlier-line treatment and leverages its dual single-domain antibody CAR design to enhance target avidity and T-cell activation. As a one-time infusion therapy with demonstrated Phase 3 benefit versus standard regimens, CARVYKTI materially strengthens the clinical and commercial case for CAR-T adoption in multiple myeloma.

What Are Latest Mergers And Acquisitions In The Carvykti Market?

In April 2023, Johnson & Johnson Services Inc., a US-based company that provides consumer healthcare products, and Legend Biotech, a US-based biotechnology company, partnered with Novartis to address supply constraints for their CAR-T therapy, carvykti (cilta-cel), which is used in treating multiple myeloma. This collaboration is a response to ongoing challenges in meeting demand, particularly due to a global shortage of viral vectors essential for cell and gene therapies. Novartis AG is a Switzerland-based pharmaceutical company that develops innovative medications including carvykti.

Regional Insights

North America was the largest region in the carvykti market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Carvykti Market?

The carvykti market consists of sales of kymriah, yescarta, breyanzi, pomalyst. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Carvykti Market Report 2026?

The carvykti market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the carvykti industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.